Thanks for the link. I wonder if Curis management is aware of this ... maybe we better tell them .....LOL.
Seriously, this and other achievements deserve some PR from this company ... why with so much to talk about is this company virtually mute about things that should create shareholder value and excitement and interest in the market? I am starting to get the perception of a degree of incompetence or indifference to the stock price by the management. Certainly the financials should/will drive some interest, but it would help if there were some PR to stoke some momentum as well.
Another good find bigL. Yes, it is only a mouse model but note that Dr. Erlichman from the Mayo clinic just recently initiated a PhII trial combining Erivedge with the approved mTOR inhibitor rapamycin (aka Sirolimus, a simpler chemical analog of RAD-001) for pancreatic cancer. Maybe this will be the magic cocktail that gets Erivedge approved for multipled tumor types. GLTAL
bigl, a big BOO YA right back at you. Great find as usual. Granted they are only mouse models but they have to start somewhere and best thing is both drugs are already approved so I would think it can move through the clinic faster as a result. I like this part:
"The team treated mice with esophageal cancer with RAD-001, GDC-0449 or both. The mTOR inhibitor RAD-001 alone had almost no effect. The Hedgehog inhibitor GDC-0449 alone reduced tumor volume by 40 percent. Together, they reduced tumor volume by 90 percent."
How many other drugs will benefit where the hedgehog is implicated in the underlying cancer by adding Erivedge to the mix? We know from various reports that hedgehog is implicated in a very high percentage of cancers (off the top of my head I can't remember the number) and this is more evidence that adding Erivedge to the treatment cycle could help make other treatments more successful. Now it is up to the scientist to figure out how best to add this to the treatment cycle.
This is just another thing that strengthens my opinion that at some point in the near future Erivedge is going to be a huge blockbuster and the resulting royalties to Curis will make it very profitable along with those of us willing to have patience. It may take a few years to figure out what our full potential is but from where I am sitting it sure looks huge in the not too distant future. GLTA and one of these days we should have a break out to the upside. Let's hope Roche is selling the heck out of Erivedge and only a few more weeks to find out about the early sales.
dd dont forget i believe there is already a ph 2 trial that dr cohen discussed in one of the youtube vids posted awhile back discussing bcc. if erivedge alone has impact the speed to which this is used could be very quick since its such a deadly cancer.
keep on accumulating!